Mednext Biotech Limited

Mednext Biotech Limited is a public limited company incorporated on August 17, 2012, in Udaipur, Rajasthan, India. The company is registered under the Corporate Identification Number (CIN) U24232RJ2012PLC039813. It has an authorized capital of ₹2.00 crore and a paid-up capital of ₹1.00 crore. Mednext Biotech Limited specializes in the manufacturing and marketing of pharmaceutical products, offering a diverse range of formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans various therapeutic categories, such as antibiotics, advanced antibiotics, and nutritional supplements.

The registered office of Mednext Biotech Limited is located at 1st Floor, 30 Mahaveer Nagar New Bhupalpura, Udaipur, Rajasthan, 313001, India. As of the latest available data, the company employs a workforce of 33 professionals. Mednext Biotech Limited is unlisted and operates as a non-government company limited by shares.

Mednext Biotech Limited operates state-of-the-art manufacturing facilities in Udaipur, Rajasthan, India. These facilities are WHO-GMP qualified and certified, ensuring adherence to international quality standards. The manufacturing plant specializes in producing a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company also offers nutraceuticals, Ayurvedic products, and cosmetics, catering to diverse healthcare needs.

Mednext Biotech Limited is led by a team of experienced professionals. Mr. Anil Kumar Vyas serves as the Director, bringing over 30 years of experience in the pharmaceutical sector. Dr. Neelam Vyas, holding a master's degree in Geography and a doctorate in Environmental Geography, is also a Director, overseeing the financial operations of the organization. Other key executives include Shriansh Vyas, appointed as an Additional Director on February 8, 2025, and Sunil Chittora, who joined as a Director on February 3, 2018.

Mednext Biotech Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds WHO-GMP certifications, which are recognized by regulatory authorities in these regions, facilitating market access. While specific regulatory filings and approvals in these markets are not detailed in the available sources, the WHO-GMP certification indicates compliance with international manufacturing standards, enhancing the company's credibility in these markets.

Mednext Biotech Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enables it to meet the regulatory requirements of these regions, facilitating market entry and acceptance. By adapting its product offerings to the specific healthcare needs of various cultures, Mednext Biotech Limited aims to provide affordable and quality healthcare solutions globally.

Mednext Biotech Limited's geographic strategy demonstrates a balanced approach, with a significant focus on both domestic and international markets. The company's substantial export value of $2.6 million USD across 54 shipments indicates a strong international presence. The portfolio concentration, with the top five products accounting for 100% of exports, suggests a strategic focus on key products. This approach mitigates concentration risk and aligns with the company's mission to provide affordable healthcare solutions worldwide.

Specific details regarding Mednext Biotech Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a prerequisite for FDA approvals. To obtain detailed information on FDA approvals and inspection history, it is recommended to consult the FDA's official database or contact the company directly.

Mednext Biotech Limited holds WHO-GMP certification, ensuring compliance with international manufacturing standards. This certification facilitates market access in various regions, including the European Union. While specific EU GMP certificates or EDQM status are not detailed in the available sources, the WHO-GMP certification serves as a recognized standard in the pharmaceutical industry, enhancing the company's credibility in regulated markets.

Mednext Biotech Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's WHO-GMP certification aligns with CDSCO's standards for pharmaceutical manufacturing. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided sources. For comprehensive information, it is advisable to consult the CDSCO's official records or contact the company directly.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Mednext Biotech Limited. The absence of such records suggests a favorable regulatory standing. However, for the most current and detailed information, it is recommended to consult the FDA's official database or contact the company directly.

Mednext Biotech Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as antibiotics, advanced antibiotics, and nutritional supplements. While specific market share comparisons and head-to-head analyses are not detailed in the available sources, the company's focus on quality manufacturing, as evidenced by its WHO-GMP certification, positions it favorably in the market. The company's strategic focus on key products, as indicated by its export portfolio concentration, suggests a targeted approach to market competition.

Mednext Biotech Limited's key differentiators include its WHO-GMP certification, which ensures adherence to international manufacturing standards, and its diverse product portfolio encompassing tablets, capsules, syrups, injections, nutraceuticals, Ayurvedic products, and cosmetics. The company's strategic focus on key products, with the top five products accounting for 100% of exports, indicates a targeted approach to market needs.

Mednext Biotech Limited's current strategic direction emphasizes the manufacturing and marketing of a diverse range of pharmaceutical products, including generics, specialty products, and nutraceuticals. The company's WHO-GMP certification and focus on quality manufacturing underscore its commitment to meeting international standards. Looking ahead, Mednext Biotech Limited aims to expand its global footprint by adapting its product offerings to the specific healthcare needs of various cultures, thereby enhancing its strategic position in the global pharmaceutical market.

Mednext Biotech Limited demonstrates a strong track record in pharmaceutical manufacturing, as evidenced by its WHO-GMP certification and diverse product portfolio. The company's export volume of $2.6 million USD across 54 shipments indicates consistent international trade activity. The portfolio concentration, with the top five products accounting for 100% of exports, suggests a focused and reliable supply chain. These factors collectively indicate Mednext Biotech Limited's reliability as a supplier in the pharmaceutical industry.

Importers should verify the following certifications when considering Mednext Biotech Limited as a supplier:

• WHO-GMP Certification: This certification ensures that the manufacturing processes meet international quality standards. Verification can be done by requesting a copy of the certificate from the company or consulting the WHO's official records.

• EU GMP Certificate: If applicable, this certificate indicates compliance with European manufacturing standards. Verification can be done by requesting a copy of the certificate from the company or consulting the European Medicines Agency (EMA).

• FDA Registration: If the company exports to the United States, FDA registration is essential. Verification can be done by checking the FDA's official database or requesting registration details from the company.

• ISO Certification: ISO certifications related to quality management systems (e.g., ISO 9001) can further validate the company's commitment to quality. Verification can be done by requesting a copy of the certificate from the company or consulting the International Organization for Standardization (ISO).

When conducting due diligence on Med